Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane ...

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break ...

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Beyond cancer treatments, scans, and countless appointments, there is another critical factor in a patient’s well-being: ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...